273 related articles for article (PubMed ID: 25820617)
21. Description of a bivalent cannabinoid ligand with hypophagic properties.
Fernández-Fernández C; Decara J; Bermúdez-Silva FJ; Sánchez E; Morales P; Gómez-Cañas M; Gómez-Ruíz M; Callado LF; Goya P; Rodríguez de Fonseca F; Martín MI; Fernández-Ruíz J; Meana JJ; Jagerovic N
Arch Pharm (Weinheim); 2013 Mar; 346(3):171-9. PubMed ID: 23371794
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
Nimczick M; Pemp D; Darras FH; Chen X; Heilmann J; Decker M
Bioorg Med Chem; 2014 Aug; 22(15):3938-46. PubMed ID: 24984935
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
Garai S; Schaffer PC; Laprairie RB; Janero DR; Pertwee RG; Straiker A; Thakur GA
Bioorg Med Chem; 2021 Nov; 50():116421. PubMed ID: 34634617
[TBL] [Abstract][Full Text] [Related]
24. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
25. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
Patel M; Finlay DB; Glass M
Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
[TBL] [Abstract][Full Text] [Related]
26. Marine cyanobacterial fatty acid amides acting on cannabinoid receptors.
Montaser R; Paul VJ; Luesch H
Chembiochem; 2012 Dec; 13(18):2676-81. PubMed ID: 23143757
[TBL] [Abstract][Full Text] [Related]
27. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
[TBL] [Abstract][Full Text] [Related]
28. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
Janero DR; Thakur GA
Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
[TBL] [Abstract][Full Text] [Related]
29. A Guide to Targeting the Endocannabinoid System in Drug Design.
Stasiulewicz A; Znajdek K; Grudzień M; Pawiński T; Sulkowska AJI
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316328
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
Morales P; Hernandez-Folgado L; Goya P; Jagerovic N
Expert Opin Ther Pat; 2016 Jul; 26(7):843-56. PubMed ID: 27215781
[TBL] [Abstract][Full Text] [Related]
31. Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.
Janero DR; Yaddanapudi S; Zvonok N; Subramanian KV; Shukla VG; Stahl E; Zhou L; Hurst D; Wager-Miller J; Bohn LM; Reggio PH; Mackie K; Makriyannis A
ACS Chem Neurosci; 2015 Aug; 6(8):1400-10. PubMed ID: 25978068
[TBL] [Abstract][Full Text] [Related]
32. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
33. Computational Investigations on the Binding Mode of Ligands for the Cannabinoid-Activated G Protein-Coupled Receptor GPR18.
Neumann A; Engel V; Mahardhika AB; Schoeder CT; Namasivayam V; Kieć-Kononowicz K; Müller CE
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365486
[TBL] [Abstract][Full Text] [Related]
34. Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells.
Capozzi A; Mattei V; Martellucci S; Manganelli V; Saccomanni G; Garofalo T; Sorice M; Manera C; Misasi R
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29973514
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, biological evaluation and binding mode modeling of benzimidazole derivatives targeting the cannabinoid receptor type 1.
Espinosa-Bustos C; Lagos CF; Romero-Parra J; Zárate AM; Mella-Raipán J; Pessoa-Mahana H; Recabarren-Gajardo G; Iturriaga-Vásquez P; Tapia RA; Pessoa-Mahana CD
Arch Pharm (Weinheim); 2015 Feb; 348(2):81-8. PubMed ID: 25641513
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists.
Mohr F; Hurrle T; Burggraaff L; Langer L; Bemelmans MP; Knab M; Nieger M; van Westen GJP; Heitman LH; Bräse S
Eur J Med Chem; 2021 Aug; 220():113354. PubMed ID: 33915369
[TBL] [Abstract][Full Text] [Related]
37. Elucidation of partial activation of cannabinoid receptor type 2 and identification of potential partial agonists: Molecular dynamics simulation and structure-based virtual screening.
Uba AI; Aluwala H; Liu H; Wu C
Comput Biol Chem; 2022 Aug; 99():107723. PubMed ID: 35850049
[TBL] [Abstract][Full Text] [Related]
38. Impact of fusion to Gα(i2) and co-expression with RGS proteins on pharmacological properties of human cannabinoid receptors CB₁R and CB₂R.
Sutor S; Heilmann J; Seifert R
J Pharm Pharmacol; 2011 Aug; 63(8):1043-55. PubMed ID: 21718288
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid Receptors in Diabetic Kidney Disease.
Barutta F; Mastrocola R; Bellini S; Bruno G; Gruden G
Curr Diab Rep; 2018 Feb; 18(2):9. PubMed ID: 29399721
[TBL] [Abstract][Full Text] [Related]
40. Advances Towards The Discovery of GPR55 Ligands.
Morales P; Jagerovic N
Curr Med Chem; 2016; 23(20):2087-100. PubMed ID: 27109575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
